Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Clinical data from the SURMOUNT trials showed that the dual approach produced 22.5% body weight reduction at the highest dose, compared to roughly 15% for semaglutide monotherapy
Participants on semaglutide lost an average of nearly 15% of body weight, while those on the highest dose of tirzepatide lost more than 20%, both over roughly 16 to 17 months of treatment
Healthcare providers must remain vigilant for delayed or uncommon side effects
FASEB j 22:659661
Weight management is the goal of all obesity treatment plans (6)
Found can connect eligible patients with clinicians who evaluate weight-loss medication options
US$ 24.50
US$ 29.96
US$ 29.57
US$ 23.38
